
TY  - JOUR
TI  - THE CARDIAC SOCIETY OF AUSTRALIA AND NEW ZEALAND
JO  - Australian and New Zealand Journal of Medicine
VL  - 30
IS  - 1
SN  - 0004-8291
UR  - https://doi.org/10.1111/j.1445-5994.2000.tb01077.x
DO  - doi:10.1111/j.1445-5994.2000.tb01077.x
SP  - 113
EP  - 190
PY  - 2000
ER  - 

TY  - JOUR
TI  - Poster Session 2
JO  - European Journal of Heart Failure Supplements
JA  - European Journal of Heart Failure Supplements
VL  - 10
IS  - S1
SN  - 1567-4215
UR  - https://doi.org/10.1093/eurjhf/hsr005
DO  - doi:10.1093/eurjhf/hsr005
SP  - S60
EP  - S104
PY  - 2011
ER  - 

C7  - pp. 80-132
TI  - Skin and Soft Tissue Lesions
SN  - 9781444334340
UR  - https://doi.org/10.1002/9781118757017.ch2
DO  - doi:10.1002/9781118757017.ch2
SP  - 80-132
KW  - bone sarcomas
KW  - malignant melanoma
KW  - nonpigmented skin cancer
KW  - skin lesions
KW  - soft tissue tumours
PY  - 2011
AB  - Summary This chapter first presents some key notes on benign nonpigmented skin lesions and benign pigmented skin lesions. Nonpigmented skin cancer is the most common malignancy in the Western world: basal cell carcinoma (BCC); squamous cell carcinoma (SCC); merkel cell carcinoma (MCC); and sebaceous carcinoma. The chapter discusses malignant nonpigmented skin lesions in detail. It then explains malignant melanoma. A melanoma ? or malignant melanoma (MM) ? is a malignant tumour of melanocytes. Next, the chapter describes vascular anomalies that are generally managed by a multidisciplinary team (MDT) of specialists in supraregional centres. It then presents a brief discussion of soft tissue tumours and bone sarcomas.
ER  - 

TY  - JOUR
TI  - Research Abstract Program of the 15th Annual ACVIM Forum
JO  - Journal of Veterinary Internal Medicine
VL  - 11
IS  - 2
SN  - 9781444334340
UR  - https://doi.org/10.1111/j.1939-1676.1997.tb00082.x
DO  - doi:10.1111/j.1939-1676.1997.tb00082.x
SP  - 97
EP  - 151
PY  - 1997
ER  - 

TY  - JOUR
TI  - Poster Session 1, Sunday 5 September
JO  - European Journal of Neurology
VL  - 11
IS  - s2
SN  - 9781444334340
UR  - https://doi.org/10.1111/j.1468-1331.2004.00919.x
DO  - doi:10.1111/j.1468-1331.2004.00919.x
SP  - 36
EP  - 182
PY  - 2004
ER  - 

TY  - JOUR
TI  - Main Topic Stroke
JO  - European Journal of Neurology
VL  - 5
IS  - S3
SN  - 9781444334340
UR  - https://doi.org/10.1111/j.1468-1331.1998.tb00466.x
DO  - doi:10.1111/j.1468-1331.1998.tb00466.x
SP  - S72
EP  - S117
PY  - 1998
ER  - 

TY  - JOUR
TI  - Posters
JO  - Journal of Peptide Science
JA  - J. Peptide Sci.
VL  - 16
IS  - S1
SN  - 9781444334340
UR  - https://doi.org/10.1002/psc.1303
DO  - doi:10.1002/psc.1303
SP  - 48
EP  - 206
PY  - 2010
ER  - 

C7  - pp. 129-160
TI  - Low-Molecular-Weight Heparins
SN  - 9780470319383
UR  - https://doi.org/10.1002/9780470518137.ch6
DO  - doi:10.1002/9780470518137.ch6
SP  - 129-160
KW  - atherothrombotic cardiovascular diseases
KW  - thrombotic vascular disease pathogenesis
KW  - adjunctive antiplatelet medications
KW  - intracranial hemorrhage
KW  - anticoagulation and pulmonary embolism
PY  - 2010
AB  - Summary This chapter contains sections titled: Introduction Comparisons between UH and LMWH Clinical uses of LMWH Conclusions References
ER  - 

TY  - JOUR
TI  - The First Iranian Annual Congress on Progress in Tissue Engineering and Regenerative MedicineAbstracts
JO  - Artificial Organs
JA  - Artificial Organs
VL  - 37
IS  - 7
SN  - 9780470319383
UR  - https://doi.org/10.1111/aor.12136
DO  - doi:10.1111/aor.12136
SP  - A27
EP  - A50
PY  - 2013
ER  - 

TY  - JOUR
AU  - Kozuch, P. L.
AU  - Brandt, L. J.
TI  - Review article: diagnosis and management of mesenteric ischaemia with an emphasis on pharmacotherapy
JO  - Alimentary Pharmacology & Therapeutics
VL  - 21
IS  - 3
SN  - 9780470319383
UR  - https://doi.org/10.1111/j.1365-2036.2005.02269.x
DO  - doi:10.1111/j.1365-2036.2005.02269.x
SP  - 201
EP  - 215
PY  - 2005
AB  - Summary Mesenteric ischaemia results from decreased blood flow to the bowel, causing cellular injury from lack of oxygen and nutrients. Acute mesenteric ischaemia (AMI) is an uncommon disorder with high morbidity and mortality, but outcomes are improved with prompt recognition and aggressive treatment. Five subgroups of AMI have been identified, with superior mesenteric artery embolism (SMAE) the most common. Older age and cardiovascular disease are common risk factors for AMI, excepting acute mesenteric venous thrombosis (AMVT), which affects younger patients with hypercoaguable states. AMI is characterized by sudden onset of abdominal pain; a benign abdominal exam may be observed prior to bowel infarction. Conventional angiography and more recently, computed tomography angiography, are the cornerstones of diagnosis. Correction of predisposing conditions, volume resuscitation and antibiotic treatment are standard treatments for AMI, and surgery is mandated in the setting of peritoneal signs. Intra-arterial vasodilators are used routinely in the treatment of non-occlusive mesenteric ischaemia (NOMI) and also are advocated in the treatment of occlusive AMI to decrease associated vasospasm. Thrombolytics have been used on a limited basis to treat occlusive AMI. A variety of agents have been studied in animal models to treat reperfusion injury, which sometimes can be more harmful than ischaemic injury. Chronic mesenteric ischaemia (CMI) usually is caused by severe obstructive atherosclerotic disease of two or more splanchnic vessels, presents with post-prandial pain and weight loss, and is treated by either surgical revascularization or percutaneous angioplasty and stenting.
ER  - 

TY  - JOUR
TI  - ARA Scientific Posters
JO  - Internal Medicine Journal
VL  - 40
IS  - s3
SN  - 9780470319383
UR  - https://doi.org/10.1111/j.1445-5994.2010.02235_1.x
DO  - doi:10.1111/j.1445-5994.2010.02235_1.x
SP  - 5
EP  - 36
PY  - 2010
ER  - 

TY  - JOUR
TI  - 17th Annual Meeting European Tissue Repair Society Measurements in Wound Healing â€“ the conduit between the laboratory and the clinic
JO  - Wound Repair and Regeneration
VL  - 15
IS  - 6
SN  - 9780470319383
UR  - https://doi.org/10.1111/j.1524-475X.2007.00319.x
DO  - doi:10.1111/j.1524-475X.2007.00319.x
SP  - A111
EP  - A151
PY  - 2007
ER  - 

TY  - JOUR
TI  - FROM THE ARCHIVES
JO  - ANZ Journal of Surgery
VL  - 77
IS  - 12
SN  - 9780470319383
UR  - https://doi.org/10.1111/j.1445-2197.2007.04326.x
DO  - doi:10.1111/j.1445-2197.2007.04326.x
SP  - 1070
EP  - 1094
PY  - 2007
AB  - The Australian and New Zealand Journal of Surgery was first published in June 1931 ?Under the Direction of the Editorial Committee of The Royal Australasian College of Surgeons?. The following synopses of articles are a biopsy of the abundant material that lies within the Journal?s archives. Although the Journal has made slight changes to its name over the years, only the current title has been used to avoid confusion. ???The Editors
ER  - 

TY  - JOUR
TI  - AASLD Abstracts
JO  - Hepatology
JA  - Hepatology
VL  - 56
IS  - S1
SN  - 9780470319383
UR  - https://doi.org/10.1002/hep.26040
DO  - doi:10.1002/hep.26040
SP  - 191A
EP  - 1144A
PY  - 2012
ER  - 

TY  - JOUR
TI  - Poster session 1
JO  - European Journal of Neurology
VL  - 14
IS  - s1
SN  - 9780470319383
UR  - https://doi.org/10.1111/j.1468-1331.2007.01936.x
DO  - doi:10.1111/j.1468-1331.2007.01936.x
SP  - 32
EP  - 163
PY  - 2007
ER  - 

TY  - JOUR
AU  - Alvarez, Ofelia A.
AU  - Zimmerman, Grenith
TI  - Pegaspargase-induced pancreatitis
JO  - Medical and Pediatric Oncology
JA  - Med. Pediatr. Oncol.
VL  - 34
IS  - 3
SN  - 9780470319383
UR  - https://doi.org/10.1002/(SICI)1096-911X(200003)34:3<200::AID-MPO7>3.0.CO;2-T
DO  - doi:10.1002/(SICI)1096-911X(200003)34:3<200::AID-MPO7>3.0.CO;2-T
SP  - 200
EP  - 205
KW  - pegaspargase - PEG - L-asparaginase
KW  - L-asparaginase
KW  - pancreatitis
KW  - childhood leukemia
PY  - 2000
AB  - Abstract Background The purpose of this study is to report the incidence of pancreatitis in patients treated with pegaspargase in our hospital during a 2-year period. Procedure We identified episodes of pancreatitis related to the intramuscular administration of pegaspargase 2,500 IU/m2 for the treatment of childhood hematological malignancies during a 2-year period (May 1996?April 1998). Patients were evaluated clinically and by sequential serum amylase and lipase determinations and radiographic examinations. For comparison, episodes of pancreatitis in patients who only received native Escherichia coli L-asparaginase were examined during the same time period. Results Nine children with acute lymphoblastic leukemia (ALL) of 50 (18%) patients who received pegaspargase were diagnosed to have pancreatitis. All had prior therapy with native L-asparaginase. These children developed symptoms consisting of abdominal pain, nausea, vomiting, and decreased appetite within a median of 15 days from the onset of pegaspargase administration. Six patients became symptomatic after their initial dose. Seven patients developed severe or unacceptable toxicity (grades 3 and 4), measured by increased amylase (>2 times normal) and lipase levels or radiographic evidence of pancreatic inflammation or pseudocyst. One patient also developed hyperammonemia and encephalopathy. In contrast, only one out of 52 (1.9%) ALL patients who received native E. coli L-asparaginase during the same time period developed pancreatitis (P= 0.007). Conclusion Clinicians should be aware of a possible higher incidence of pancreatitis associated with pegaspargase. Med Pediatr Oncol 34:200?205, 2000. ? 2000 Wiley-Liss, Inc.
ER  - 

TY  - JOUR
TI  - Poster Presentations
JO  - The FEBS Journal
VL  - 278
IS  - s1
SN  - 9780470319383
UR  - https://doi.org/10.1111/j.1742-4658.2011.08137.x
DO  - doi:10.1111/j.1742-4658.2011.08137.x
SP  - 74
EP  - 445
PY  - 2011
ER  - 

TY  - JOUR
TI  - POSTER SESSIONS
JO  - Allergy
VL  - 63
IS  - s88
SN  - 9780470319383
UR  - https://doi.org/10.1111/j.1398-9995.2008.01760.x
DO  - doi:10.1111/j.1398-9995.2008.01760.x
SP  - 158
EP  - 611
PY  - 2008
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Pharmacoepidemiology and Drug Safety
JA  - Pharmacoepidemiol Drug Saf
VL  - 28
IS  - S2
SN  - 9780470319383
UR  - https://doi.org/10.1002/pds.4864
DO  - doi:10.1002/pds.4864
SP  - 5
EP  - 586
PY  - 2019
ER  - 

TY  - JOUR
TI  - Poster Sessions
JO  - Neurogastroenterology & Motility
VL  - 24
IS  - s2
SN  - 9780470319383
UR  - https://doi.org/10.1111/j.1365-2982.2012.01997.x
DO  - doi:10.1111/j.1365-2982.2012.01997.x
SP  - 43
EP  - 190
PY  - 2012
ER  - 
